| A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (NCT04442126) | Numab Therapeutics AG | 2020-08-19 |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (NCT04504669) | AstraZeneca | 2020-08-18 |
| A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer (NCT04398940) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-08-11 |
| A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies (NCT04440943) | Celldex Therapeutics | 2020-08-04 |
| The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance (NCT04450043) | Massachusetts General Hospital | 2020-08-01 |
| Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume (NCT04430712) | Massachusetts General Hospital | 2020-08-01 |
| Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation (NCT03758677) | The First Hospital of Jilin University | 2020-08-01 |
| A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC (NCT04636593) | First People's Hospital of Hangzhou | 2020-08-01 |
| NEUWAVE Flexible Probe Study #2 (NCT03713099) | Ethicon, Inc. | 2020-07-31 |
| Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial (NCT04316013) | Peter MacCallum Cancer Centre, Australia | 2020-07-31 |
| INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) (NCT04203511) | Incyte Corporation | 2020-07-31 |
| Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC (NCT04153097) | First Affiliated Hospital of Zhejiang University | 2020-07-30 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (NCT04449874) | Genentech, Inc. | 2020-07-29 |
| Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer (NCT04379739) | Shanghai Pulmonary Hospital, Shanghai, China | 2020-07-26 |
| eRAPID: Online Symptom Reporting in Lung Cancer (NCT04324437) | University of Leeds | 2020-07-20 |
| Evaluation of GLR2007 for Advanced Solid Tumors (NCT04444427) | Gan and Lee Pharmaceuticals, USA | 2020-07-15 |
| Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC (NCT04405674) | Shanghai Chest Hospital | 2020-07-15 |
| Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) (NCT04245514) | Swiss Cancer Institute | 2020-07-15 |
| A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC (NCT04316364) | Jiangsu HengRui Medicine Co., Ltd. | 2020-07-14 |
| A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China (NCT04121286) | Allist Pharmaceuticals, Inc. | 2020-07-14 |
| Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation (NCT04470076) | Fifth Affiliated Hospital, Sun Yat-Sen University | 2020-07-10 |
| Image Mining and ctDNA to Improve Risk Stratification and Outcome Prediction in NSCLC Applying Artificial Intelligence. (NCT06163846) | IRCCS San Raffaele | 2020-07-10 |
| Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib (NCT04099836) | Duke University | 2020-07-09 |
| A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene (NCT04395677) | Nuvation Bio Inc. | 2020-07-07 |
| A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets (NCT06507891) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-07-06 |
| A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets (NCT04273815) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-07-06 |
| Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer (NCT04212052) | Sun Yat-sen University | 2020-07-01 |
| Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients (NCT05746598) | Ain Shams University | 2020-07-01 |
| Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer (NCT03628144) | H. Lee Moffitt Cancer Center and Research Institute | 2020-07-01 |
| Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE） (NCT04459611) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-07-01 |
| Identify Prognostic Biomarkers of Lung Cancer (NCT05010330) | RenJi Hospital | 2020-07-01 |
| A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression (NCT04274907) | AbbVie | 2020-06-30 |
| Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment (NCT04263090) | Icahn School of Medicine at Mount Sinai | 2020-06-29 |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies (NCT04383938) | Aprea Therapeutics | 2020-06-25 |
| Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab (NCT04074967) | Dan Zandberg | 2020-06-11 |
| Tumor Mutational Burden in Lung Cancer Patients (NCT04289259) | Assistance Publique - Hôpitaux de Paris | 2020-06-10 |
| NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (NCT04332653) | NeoImmuneTech | 2020-06-10 |
| Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) (NCT04314089) | Edward Patz | 2020-06-09 |
| Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLC (NCT04524299) | Sun Yat-sen University | 2020-06-01 |
| cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors (NCT04069442) | University Hospital, Grenoble | 2020-06-01 |
| Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors (NCT04355806) | Shanghai Pulmonary Hospital, Shanghai, China | 2020-06-01 |
| Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy (NCT05314296) | N.N. Blokhin National Medical Research Center of Oncology | 2020-06-01 |
| Bioimaging Study of 89Zr-M7824 in NSCLC (NCT04297748) | Olivia Newton-John Cancer Research Institute | 2020-06-01 |
| Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer (NCT04397926) | Sun Yat-sen University | 2020-05-30 |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer (NCT04254107) | Seagen Inc. | 2020-05-29 |
| Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) (NCT04379635) | BeiGene | 2020-05-29 |
| Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (NCT04262856) | Arcus Biosciences, Inc. | 2020-05-28 |
| SBRT Dose Escalation for Reirradiation of Inoperable Lung Lesions (NCT04455438) | Istituto Clinico Humanitas | 2020-05-28 |
| The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy (NCT04667975) | Chong Kun Dang Pharmaceutical | 2020-05-21 |
| Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer (NCT04487093) | First Hospital of Shijiazhuang City | 2020-05-17 |
| Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays (NCT04074993) | JI-YOUN HAN | 2020-05-15 |
| Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 (NCT04297605) | University of Rochester | 2020-05-15 |
| αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors (NCT04489862) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2020-05-13 |
| Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study (NCT04392505) | Oslo University Hospital | 2020-05-11 |
| Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC (NCT04371796) | Sichuan Cancer Hospital and Research Institute | 2020-05-10 |
| Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT04384146) | Memorial Sloan Kettering Cancer Center | 2020-05-07 |
| Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors (NCT04344795) | Tempest Therapeutics | 2020-05-06 |
| A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers (NCT04272203) | AbbVie | 2020-05-05 |
| Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib (NCT04358562) | Second Affiliated Hospital of Nanchang University | 2020-05-01 |
| I-125 Seeds Implantation in the Treatment of Recurrent Lung Cancer After Radiotherapy (NCT04071418) | Peking University Third Hospital | 2020-05-01 |
| Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer (NCT05257512) | Shouyao Holdings (Beijing) Co. LTD | 2020-04-26 |
| Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors (NCT04374877) | Coherus Oncology, Inc. | 2020-04-22 |
| A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients (NCT03485326) | AstraZeneca | 2020-04-21 |
| Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (NCT04322890) | Hunan Province Tumor Hospital | 2020-04-16 |
| A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients (NCT04312308) | Yonsei University | 2020-04-08 |
| Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer (NCT04003246) | University of Texas Southwestern Medical Center | 2020-04-03 |
| Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit (NCT05360225) | QIAGEN Gaithersburg, Inc | 2020-04-02 |
| Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC (NCT04322578) | Hunan Province Tumor Hospital | 2020-03-24 |
| Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC (NCT04324151) | Hunan Province Tumor Hospital | 2020-03-24 |
| Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC (NCT04324164) | Hunan Province Tumor Hospital | 2020-03-24 |
| Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial (NCT04322591) | Hunan Province Tumor Hospital | 2020-03-24 |
| Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC (NCT04324125) | Hunan Province Tumor Hospital | 2020-03-24 |
| Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer (NCT04322617) | Hunan Province Tumor Hospital | 2020-03-24 |
| Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies (NCT04181788) | Pfizer | 2020-03-18 |
| Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit (NCT05347797) | QIAGEN Gaithersburg, Inc | 2020-03-13 |
| PD-L1 Expression in Cancer (PECan Study). (NCT04436406) | Guy's and St Thomas' NHS Foundation Trust | 2020-03-11 |
| Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) (NCT04123379) | Icahn School of Medicine at Mount Sinai | 2020-03-05 |
| A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NCT04294810) | Hoffmann-La Roche | 2020-03-04 |
| Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion (NCT04263688) | Guangzhou Institute of Respiratory Disease | 2020-03-01 |
| Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC (NCT04304638) | Chinese Academy of Medical Sciences | 2020-03-01 |
| A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NCT04250246) | Italian Network for Tumor Biotherapy Foundation | 2020-03-01 |
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (NCT04152499) | Klus Pharma Inc. | 2020-02-28 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (NCT04194944) | Eli Lilly and Company | 2020-02-17 |
| Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) (NCT04248829) | Yuhan Corporation | 2020-02-13 |
| A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies (NCT04244552) | Atreca, Inc. | 2020-02-11 |
| Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab (NCT04791215) | Columbia University | 2020-02-01 |
| A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT04239833) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2020-01-31 |
| Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma (NCT04173338) | Augusta University | 2020-01-23 |
| Deciphering Mechanisms Underlying Cancer Immunogenicity (NCT03958240) | Institut Claudius Regaud | 2020-01-17 |
| A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG) (NCT04258033) | Beijing Pearl Biotechnology Limited Liability Company | 2020-01-17 |
| Green Tea Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer (NCT04160559) | Xinqiao Hospital of Chongqing | 2020-01-11 |
| EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer (NCT04159025) | Washington University School of Medicine | 2020-01-08 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors (NCT04198818) | Haihe Biopharma Co., Ltd. | 2020-01-07 |
| Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma (NCT04189679) | University Hospital, Grenoble | 2020-01-03 |
| Factors Determine the Feasibility and Surgical Margin Quality of Sublobar Resection for Non-small Cell Lung Cancer? (NCT07005401) | The First Affiliated Hospital with Nanjing Medical University | 2020-01-01 |
| Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC (NCT04345146) | Sun Yat-sen University | 2020-01-01 |
| Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer (NCT04211896) | The First Affiliated Hospital with Nanjing Medical University | 2020-01-01 |
| Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer (NCT05212285) | Fudan University | 2020-01-01 |
| D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC (NCT04206072) | Betta Pharmaceuticals Co., Ltd. | 2019-12-24 |
| Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection (NCT04238130) | Sun Yat-sen University | 2019-12-18 |